๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Shanghai
Clinical trial register · China

Clinical Trials in Shanghai, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Shanghai 23 Beijing 20 Guangzhou 14 Hangzhou 13 Tianjin 8
Narrow the registerReset
Recruitment status
Phase
Site location
Shanghai23 Beijing20 Guangzhou14 Hangzhou13 Tianjin8
All 38 locations
Target enrolment
to

Trials with a site in Shanghai

23 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Not yet open
A Study to Evaluate the Efficacy and Safety of AK139 in Participants With Chronic Rhinosinusitis With Nasal Polyps
NCT07755371Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)
DrugAK139
Akeso
Phase 2
75
Shanghai
2026-08-10
Recruiting
A Phase II Study of AK146D1 Combined With AK112 in Advanced Breast Cancer
NCT07591090Advanced Breast Cancer
Akeso
Phase 2
200
Shanghai
2026-07-17
Recruiting
A Study of AK138D1 Alone or in Combination With Ivonescimab in Advanced Non-Small Cell Lung Cancer
NCT07623356Non-Small Cell Lung Cancer
Akeso
Phase 1/2
265
Shanghai
2026-07-07
Not yet open
A Phase II Study of AK146D1 Mono or Combined With AK112 in Advanced Urothelial Carcinoma
NCT07636772Urothelial Carcinoma (UC)
Akeso
Phase 2
132
Shanghai
2026-06-22
Not yet open
A Study to Evaluate the Efficacy and Safety of AK139 in Participants With Asthma
NCT07436221Asthma
Akeso
Phase 2
160
Guangzhou, Shanghai
2026-02-28
Recruiting
A Study of Ivonescimab in First-Line ES-SCLC
NCT07245446Extensive-stage Small Cell Lung Cancer (ES-SCLC)
Akeso
Phase 2
180
Beijing, Xi'an, Shanghai
2025-10-29
Recruiting
A Study of AK130 in Combination With AK112 for the Treatment of Advanced Pancreatic Cancer
NCT07114315Pancreatic Cancer
Akeso
Phase 2
160
Shanghai, Tianjin
2025-09-19
Recruiting
A Phase III Clinical Study of Cadonilimab Plus SOX as Perioperative Treatment for Patients With Resectable G/GEJ Adenocarcinoma
NCT07023315Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma
Akeso
Phase 3
760
Beijing, Fuzhou, Shijiazhuang, Harbin, Shanghai, Tianjin
2025-08-14
Not yet open
A Study of mRNA Vaccines AK154 Monotherapy or in Combination With AK104/AK112,and Sequential mFOLFIRINOX in Surgically Resected PDAC
NCT06913218Pancreas Cancer, Pancreas Cancer, Duct Cell Adenocarcinoma
Akeso
Phase 1
60
Shanghai
2025-07-22
Recruiting
Ivonescimab in Combination With Docetaxel in Advanced Non-Small Cell Lung Cancer
NCT06928389Non-Small Cell Lung Cancer
Akeso
Phase 3
536
Shanghai
2025-07-08
Recruiting
A Phase III Study of Ivonescimab + Chemo With/Without AK117 in Metastatic Pancreatic Cancer
NCT06953999Pancreatic Cancer
Akeso
Phase 3
999
Harbin, Shanghai, Hangzhou
2025-06-11
Not yet open
AK135 in Patients With Chemotherapy-Induced Peripheral Neuropathy (CIPN)
NCT06860789Chemotherapy-induced Peripheral Neuropathy (CIPN)
Akeso
Phase 1
85
Guangzhou, Shanghai
2025-02-28
Not yet open
AK137 (Bispecific Antibody Targeting CD73 and LAG-3) in Patients With Advanced Malignant Tumors
NCT06691360Advanced Malignant Tumors
Akeso
Phase 1
87
Shanghai
2024-12
Recruiting
An Exploratory, Multi-cohort Phase II Study of Combination Therapy With AK104 and AK112 for Recurrent Ovarian Cancer
NCT06560112Recurrent Ovarian Cancer
Akeso
Phase 2
172
Shanghai
2024-11-12
Active, closed
AK112 Combined With Chemotherapy Versus Durvalumab Combined With Chemotherapy in Advanced Biliary Tract Cancer
NCT06591520Biliary Tract Cancer
Akeso
Phase 3
682
Harbin, Shanghai
2024-10-20
Active, closed
AK112 in Combination With Chemotherapy in Advanced Squamous Non-Small Cell Lung Cancer
NCT05840016Advanced Squamous Non Small Cell Lung Cancer
Akeso
Phase 3
532
Shanghai
2023-08-17
Active, closed
AK112 and AK104 With or Without Chemotherapy in Advanced Non-small Cell Lung Cancer
NCT05904379Advanced Non-small-cell Lung Cancer
Akeso
Phase 1/2
233
Hangzhou, Shanghai
2023-07-13
Recruiting
A Study of AK104 With Chemotherapy as First-line Treatment in Patients With Advanced Pancreatic Cancer
NCT05859750Pancreatic Cancer
Akeso
Phase 2
78
Beijing, Guangzhou, Wuhan, Jinan, Shanghai, Hangzhou
2023-05-25
Recruiting
A Phase III Study of AK104 as Adjuvant Therapy in HCC With High Risk of Recurrence After Curative Resection
NCT05489289Hepatocellular Carcinoma
Akeso
Phase 3
570
Shanghai
2023-01-05
Active, closed
AK112 in Advanced Non-Small Cell Lung Cancer
NCT05499390Advanced Non-small-cell Lung Cancer
Akeso
Phase 3
398
Shanghai
2022-11-09
Active, closed
A Study of AK104/Placebo Combined With Chemoradiotherapy For The Treatment of Locally Advanced Cervical Cancer
NCT05235516Locally Advanced Cervical Carcinoma
Akeso
Phase 3
636
Beijing, Guiyang, Wuhan, Changsha, Shanghai, Chengdu, Hangzhou
2022-06-21
Rows per page Showing 1–23 of 23
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 25 September 2026. https://priyalifescience.com/clinical-trials-china/city/shanghai

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 23 of those studies with a site in Shanghai that also match the filters currently applied.

How many clinical trials are recruiting in Shanghai?

10 of the 23 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 7 have not yet opened recruitment, 6 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Shanghai), 23 studies
PhaseStudiesRecruitingShare
Phase 310443.5%
Phase 28534.8%
Phase 13013%
Phase 1/2218.7%

Most active sponsors

Lead sponsors with the most studies (Shanghai)
Lead sponsorStudiesRecruiting
Akeso2310
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.